Monopar TherapeuticsMNPR
13F holders, Q3 2024 (September 30)6holders
$6.74avg. 13F price*
At the end of Q3 2024, 6 institutions reported holding Monopar Therapeutics Inc. (MNPR) in their 13F filings. The largest holders were Geode Capital Management, LLC ($95K), NewEdge Advisors, LLC ($4K) and UBS Group AG ($3K).
- Company
- Monopar Therapeutics Inc.
- CUSIP
- 61023L207
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $3K |
| Exits | 0 | $0 |
Ownership 6 holders
| Geode Capital Management, LLC | 0.00% | Add +17.1% | 14,066 | $95K |
| NewEdge Advisors, LLC | 0.00% | No change | 600 | $4K |
| UBS Group AG | 0.00% | New | 512 | $3K |
| Wells Fargo & Company | 0.00% | No change | 500 | $3K |
| Federation des caisses Desjardins du Quebec | 0.00% | No change | 16 | $108 |
| Bank of America Corp. | 0.00% | Reduce -88.4% | 13 | $88 |
"% of holder's portfolio" is MNPR's weight in each manager's 13F, not the share of Monopar Therapeutics Inc. the manager owns.